Oryzon Genomics Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Oryzon Genomics de 65.9% y 65.8% respectivamente, mientras que el BPA crecerá en un 64.5% al año.

Información clave

67.8%

Tasa de crecimiento de los beneficios

67.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.2%
Tasa de crecimiento de los ingresos	72.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	08 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:ORN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	4	-8	N/A	N/A	2
12/31/2025	N/A	1	N/A	N/A	3
12/31/2024	N/A	-3	N/A	N/A	3
3/31/2024	N/A	-3	N/A	N/A	N/A
12/31/2023	N/A	-4	N/A	N/A	N/A
9/30/2023	17	-4	N/A	N/A	N/A
6/30/2023	17	-4	-21	-3	N/A
3/31/2023	17	-5	N/A	N/A	N/A
12/31/2022	17	-5	-17	-2	N/A
9/30/2022	10	-3	N/A	N/A	N/A
6/30/2022	14	-5	-15	-3	N/A
3/31/2022	12	-5	N/A	N/A	N/A
12/31/2021	12	-5	-18	-4	N/A
9/30/2021	11	-4	N/A	N/A	N/A
6/30/2021	10	-4	-17	-4	N/A
3/31/2021	7	-5	N/A	N/A	N/A
12/31/2020	12	-4	-17	-6	N/A
9/30/2020	12	-4	N/A	N/A	N/A
6/30/2020	13	-4	-16	-4	N/A
3/31/2020	13	-4	N/A	N/A	N/A
12/31/2019	12	-4	-15	-4	N/A
9/30/2019	10	-4	N/A	N/A	N/A
6/30/2019	9	-4	-11	-3	N/A
3/31/2019	8	-2	N/A	N/A	N/A
12/31/2018	8	-1	-9	-1	N/A
9/30/2018	7	-2	N/A	N/A	N/A
6/30/2018	6	-2	-11	-5	N/A
3/31/2018	6	-6	N/A	N/A	N/A
12/31/2017	5	-6	N/A	-6	N/A
9/30/2017	6	-6	N/A	N/A	N/A
6/30/2017	6	-6	N/A	-4	N/A
3/31/2017	5	-6	N/A	N/A	N/A
12/31/2016	5	-6	N/A	-5	N/A
9/30/2016	6	-5	N/A	N/A	N/A
6/30/2016	6	-4	N/A	-1	N/A
3/31/2016	8	-1	N/A	N/A	N/A
12/31/2015	8	-1	N/A	1	N/A
9/30/2015	8	-1	N/A	N/A	N/A
6/30/2015	7	-1	N/A	N/A	N/A
3/31/2015	11	2	N/A	N/A	N/A
12/31/2014	19	8	N/A	15	N/A
12/31/2013	3	-3	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ORN sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.6%).

Beneficios vs. Mercado: Se prevé que ORN sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ORN sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ORN no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ORN no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ORN se prevé que sea elevada dentro de 3 años.

Oryzon Genomics Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date moved forward to 2025

Forecast breakeven date pushed back to 2026

Forecast breakeven date pushed back to 2026

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Recent updates

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast breakeven date pushed back to 2026

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

New major risk - Financial position

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

Forecast to breakeven in 2025

New major risk - Financial position

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Full year 2020 earnings released

New 90-day high: €3.75

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.10

New 90-day low: €2.64

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.65

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento